Skip to main content
. 2020 Jun 12;11:2978. doi: 10.1038/s41467-020-16789-2

Fig. 8. JZL184 inhibits M2-like TAMs signature and associated with patients survival.

Fig. 8

a Correlation dot-plot of JZL184 downregulated gene signature and M2 gene signature of TAMs from vehicle vs. JZL184-treated subcutaneous mouse model. b Representative IHC and IF images of CD44 and ARG1 in edge or core tumor regions of brain slices treated with JZL184 or vehicle. Scale bar, 100 µm. c Pie chart of ratio of GBM subtypes according to high and low expression of M2-like gene signature. d Kaplan–Meier survival plots for GBM patients in the TCGA data set according to high (top 50%) and low (bottom 50%) M2-like signature expression. e Gene Set Enrichment Analysis (GSEA) plot for stemness gene signature in comparison of TAMs from vehicle vs. JZL184-treated subcutaneous mouse model. f Kaplan–Meier survival plots for the orthotopic syngeneic mouse model (n = 4). Median survival of the orthotopic syngeneic mice treated with Vehicle, PD-1, JZL184, or PD-1+JZL184 was 26 days, 29 days, 30.5 days, and 69.5 days, respectively.